Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Conditions

Carcinoma, Renal Cell 20Gastrointestinal Stromal Tumors 9Kidney Neoplasms 6Breast Neoplasms 4Neoplasms 3Neoplasm Metastasis 3Kidney Diseases 2Carcinoma, Non-Small-Cell Lung 2Carcinoma 2Urologic Neoplasms 1Prostatic Neoplasms 1Primary Disease: Unresectable or Metastatic Renal Cell Carcinoma Focus of the Study:PFS Assessed by IRC Per RECIST 1.1 1Patient Preference 1Parkinson Disease 4, Autosomal Dominant Lewy Body 1Pancreatic Neoplasms 1Neuroendocrine Tumors 1Neoplasms by Site 1Gastrointestinal Neoplasms 1Gastro-enteropancreatic neuroendocrine tumor 1Colorectal Neoplasms 1Carcinoma, Islet Cell 1Carcinoma, Hepatocellular 1Carcinoid Tumor 1Advanced Renal Cancer 1Adenoma, Islet Cell 1

Interventions

anlotinib 1Sunitinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 3 × Advanced Renal Cancer × Sunitinib × Clear all
NCT04523272 2024-10-15

A Study of TQB2450 Injection Combined With Anlotinib Hydrochloride Capsule Versus Sunitinib in Subjects With Advanced Renal Cancer

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Phase 3 Active not recruiting
528 enrolled

Advanced Renal Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡